Biofrontera Inc BFRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BFRI is a good fit for your portfolio.
News
-
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals
-
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
-
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
-
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024
-
Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules
-
Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG
-
Biofrontera Inc. Announces Private Placement of Up To $16.0 Million Priced at Market per Nasdaq Rules
-
Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per Use
Trading Information
- Previous Close Price
- $1.45
- Day Range
- $1.41–1.52
- 52-Week Range
- $0.61–13.42
- Bid/Ask
- $1.40 / $1.54
- Market Cap
- $7.61 Mil
- Volume/Avg
- 54,109 / 712,699
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 85
- Website
- https://www.biofrontera-us.com
Valuation
|
Metric
|
BFRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.47 |
Price/Sales | 0.07 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BFRI
|
|---|---|
Quick Ratio | 0.36 |
Current Ratio | 1.28 |
Interest Coverage | −32.75 |
Quick Ratio
BFRI
Profitability
|
Metric
|
BFRI
|
|---|---|
Return on Assets (Normalized) | −56.51% |
Return on Equity (Normalized) | −202.09% |
Return on Invested Capital (Normalized) | −159.98% |
Return on Assets
BFRI
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Qgmjntzphx | Mfwccjp | $71.2 Bil | |
ZTS
| Zoetis Inc Class A | Tkhtlpmtpj | Qwmpx | $70.0 Bil | |
HLN
| Haleon PLC ADR | Dnxfkcz | Gmjwg | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Fzvjfvjv | Htj | $14.5 Bil | |
VTRS
| Viatris Inc | Zknqrsppk | Xgbvt | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Cxzzhyg | Vmx | $11.9 Bil | |
CTLT
| Catalent Inc | Zsbtrcmf | Bnvpqkm | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Nqpbqglsw | Hnks | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Zqwzrmv | Fnlc | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Yhffbnvb | Xmnwdn | $3.5 Bil |